BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25708214)

  • 41. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.
    Baron F; Ruggeri A; Beohou E; Labopin M; Mohty M; Blaise D; Cornelissen JJ; Chevallier P; Sanz G; Petersen E; Savani BN; Gluckman E; Nagler A
    J Hematol Oncol; 2017 Jun; 10(1):128. PubMed ID: 28637512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.
    Wallet HL; Sobh M; Morisset S; Robin M; Fegueux N; Fürst S; Mohty M; Deconinck E; Fouillard L; Bordigoni P; Rio B; Sirvent A; Renaud M; Dhedin N; Tabrizi R; Maury S; Buzyn A; Michel G; Maillard N; Cahn JY; Bay JO; Yakoub-Agha I; Huynh A; Schmidt-Tanguy A; Lamy T; Lioure B; Raus N; Marry E; Garnier F; Balère ML; Gluckman E; Rocha V; Socié G; Blaise D; Milpied N; Michallet M
    Exp Hematol; 2013 Nov; 41(11):924-33. PubMed ID: 23831606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
    Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
    Piñana JL; Sanz J; Esquirol A; Martino R; Picardi A; Barba P; Parody R; Gayoso J; Montesinos P; Guidi S; Terol MJ; Moscardó F; Solano C; Arcese W; Sanz MA; Sierra J; Sanz G;
    Eur J Haematol; 2016 Feb; 96(2):128-35. PubMed ID: 25845981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults.
    Narimatsu H; Terakura S; Matsuo K; Oba T; Uchida T; Iida H; Hamaguchi M; Watanabe M; Kohno A; Murata M; Sawa M; Miyamura K; Morishita Y
    Bone Marrow Transplant; 2007 Jan; 39(1):31-9. PubMed ID: 17115066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia.
    Ooi J; Takahashi S; Tomonari A; Tsukada N; Konuma T; Kato S; Kasahara S; Sato A; Monma F; Nagamura F; Iseki T; Tojo A; Asano S
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1341-7. PubMed ID: 19041055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
    Koehne G; Giralt S
    Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
    J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study.
    Okada M; Yoshihara S; Taniguchi K; Kaida K; Ikegame K; Kato R; Tamaki H; Inoue T; Soma T; Kai S; Kato S; Ogawa H
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):633-9. PubMed ID: 21867667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
    Chen YB; Aldridge J; Kim HT; Ballen KK; Cutler C; Kao G; Liney D; Bourdeau G; Alyea EP; Armand P; Koreth J; Ritz J; Spitzer TR; Soiffer RJ; Antin JH; Ho VT
    Biol Blood Marrow Transplant; 2012 May; 18(5):805-12. PubMed ID: 22015993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.